Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial

Autor: M. Gershenson, David, Miller, Austin, E Brady, William, Paul, James, Carty, Karen, Rodgers, William, Millan, David, L Coleman, Robert, N Moore, Kathleen, Banerjee, Susana, Connolly, Kate, Alvarez Secord, Angeles, M O'Malley, David, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robb, Herrington, C Simon, Q Huang, Helen, B Wenzel, Lari, Gourley, Charlie

Publikováno v: M. Gershenson, D, Miller, A, E Brady, W, Paul, J, Carty, K, Rodgers, W, Millan, D, L Coleman, R, N Moore, K, Banerjee, S, Connolly, K, Alvarez Secord, A, M O'Malley, D, Dorigo, O, Gaillard, S, Gabra, H, Slomovitz, B, Hanjani, P, Farley, J, Churchman, M, Ewing, A, Hollis, R, Herrington, C S, Q Huang, H, B Wenzel, L & Gourley, C 2022, ' Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomised, open-label phase 2/3 trial ', The Lancet, vol. 399, no. 10324, pp. 541-553 . https://doi.org/10.1016/S0140-6736(21)02175-9

BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician'

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3094::10daf3830e8817199b8469c4d2ece72c
https://hdl.handle.net/20.500.11820/745251c7-7e6d-4cf1-9129-3a76f1637764